Research Summaries
Research Summaries
Evidence-Based Overviews for Scientific Reference
Concise, peer-informed research summaries for all major research peptides across five biological categories. Each summary captures mechanism of action, primary research findings, and key molecular targets — designed for researchers designing protocols and reviewing evidence.
Advanced Metabolic Peptide Summaries
Research summaries for next-generation GLP-1 receptor agonists, dual-agonists, and poly-agonist compounds exploring metabolic regulation and glycaemic control.
GLP-1 Receptor Agonist · Featured Summary
Semaglutide
Long-Acting GLP-1 Analogue
Semaglutide is a fatty-acid modified GLP-1 analogue engineered for extended half-life through reversible albumin binding. Research demonstrates potent glucose-dependent insulin secretion, glucagon suppression, and centrally mediated appetite reduction. Studies consistently show significant body weight reductions alongside improved cardiometabolic markers, establishing semaglutide as a primary reference compound for GLP-1 pathway research.
- GLP-1R agonism with ~168-hour half-life via albumin conjugation
- Hypothalamic appetite suppression through POMC neuron activation
- Glucose-dependent insulinotropic action with low hypoglycaemia risk
- Demonstrated visceral fat reduction in controlled study models
- Cardiovascular protection markers including MACE risk reduction
- Hepatic steatosis improvement in fatty liver disease research models
Tirzepatide
Twin incretin receptor co-activation for superior metabolic outcomes
Tirzepatide is a dual GIP/GLP-1 receptor co-agonist that simultaneously engages both incretin pathways, producing synergistic metabolic effects beyond those of GLP-1 monotherapy. Research models demonstrate enhanced insulin secretion, reduced glucagon, and superior weight reduction compared to single-receptor approaches.
Key Research Findings
- Dual receptor activation amplifies beta-cell glucose sensitivity
- Greater adipose tissue reduction versus GLP-1 mono-agonism in preclinical models
- Improved insulin resistance markers in metabolic syndrome study subjects
- GIP co-activation modulates bone metabolism and lipid partitioning pathways
Retatrutide
Triple incretin agonism pushing the frontier of metabolic research
Retatrutide represents the next frontier of incretin pharmacology, co-activating GLP-1, GIP, and glucagon receptors simultaneously. Research models suggest the added glucagon receptor component significantly amplifies energy expenditure, positioning retatrutide as a powerful tool for studying the upper limits of pharmacological metabolic intervention.
Key Research Findings
- Glucagon receptor co-activation increases hepatic glucose output regulation and thermogenesis
- Markedly elevated energy expenditure versus dual-agonist comparators in early models
- Liver fat reduction through combined hepatic and pancreatic pathway engagement
- Investigational candidate for severe obesity and NASH research models
GIP/GLP-1 Pathway Studies
Foundational incretin biology underpinning advanced metabolic research
Understanding the native GIP and GLP-1 incretin axes is essential context for interpreting multi-agonist research. These pathways coordinate post-prandial insulin secretion, glucagon suppression, gastric emptying, and satiety signalling — providing the mechanistic baseline against which all analogue research is evaluated.
Key Research Findings
- GLP-1 secreted from L-cells of the distal gut in response to nutrient ingestion
- GIP from K-cells of the proximal intestine; complementary insulin-potentiating action
- Both axes show reduced responsiveness in type 2 diabetes models — incretin defect hypothesis
- Combined receptor stimulation demonstrates non-additive synergism in beta-cell studies
Next-Gen Metabolic Studies
Oral delivery, CNS targeting and beyond-metabolic applications
Emerging research explores semaglutide analogues and next-generation GLP-1 compounds modified for oral bioavailability, CNS penetration, and organ-specific targeting. These investigational directions expand the research applications of the GLP-1 class into neurodegeneration, cardiovascular biology, and renal protection models.
Key Research Findings
- Oral bioavailability enhancement via SNAC absorption promoter technology
- GLP-1R expression in hippocampus and substantia nigra — neuroprotection studies
- Cardiac GLP-1R activation linked to anti-inflammatory and anti-fibrotic outcomes
- Renal GLP-1 receptor engagement reduces albuminuria markers in CKD models
Comparative Agonism Studies
Research comparing mono-, dual-, and triple-agonist compounds provides structured insight into the additive versus synergistic value of each incretin receptor engagement.
CNS & Appetite Axis
Central GLP-1 receptor expression in hypothalamic and brainstem nuclei makes these peptides valuable tools for studying the neuroendocrine regulation of energy balance.
Cardiometabolic Models
Cardiovascular outcome data from GLP-1 compound research informs understanding of the link between metabolic dysregulation, inflammation, and cardiac risk reduction.
Growth Hormone Peptide Summaries
Research overviews for the five principal growth hormone secretagogues and releasing peptides studied across somatotropic axis research programs.
CJC-1295
Extended-release GHRH analogue for sustained somatotropic axis research
CJC-1295 is a synthetic GHRH analogue modified with Drug Affinity Complex (DAC) technology that enables reversible albumin binding, extending its circulating half-life from minutes to several days. Researchers use it to study sustained GHRH receptor stimulation and chronic GH elevation without frequent administration.
Key Research Findings
- DAC technology creates a natural depot releasing active peptide over 7–10 days
- Dose-dependent IGF-1 elevation sustained across multi-week study periods
- Preserves physiological pulsatility — GH secretion remains feedback-regulated
- Lean body mass improvements observed in body composition research models
- Frequently combined with Ipamorelin to achieve complementary pituitary stimulation
Ipamorelin
High-selectivity ghrelin receptor agonist with clean GH release profile
Ipamorelin is a pentapeptide GHRP that selectively activates ghrelin receptors (GHS-R1a) without meaningfully elevating cortisol, prolactin, or ACTH. This selectivity makes it the preferred tool when researchers need isolated GH release data free from confounding endocrine changes.
Key Research Findings
- Highly selective GHS-R1a agonism — minimal off-target pituitary hormone release
- Stimulates discrete, physiological-amplitude GH pulses (~2 hr action window)
- Excellent tolerability profile for sensitive and long-duration study models
- Synergistic GH release when co-administered with GHRH analogues such as CJC-1295
- IGF-1 elevation and downstream anabolic pathway activation research
IGF-1 LR3
Long-arginine IGF-1 variant for direct downstream GH-axis research
IGF-1 LR3 is a recombinant analogue of insulin-like growth factor-1 modified to reduce IGF-binding protein affinity by over 1000-fold, dramatically extending its half-life. This allows researchers to study sustained IGF-1 receptor signalling independently of upstream GH secretion.
Key Research Findings
- Reduced IGFBP affinity prolongs active half-life to approximately 20–30 hours
- Direct IGF-1R activation drives PI3K/Akt and MAPK/ERK anabolic signalling
- Skeletal muscle satellite cell activation and protein synthesis research models
- Bypasses pituitary axis — allows isolated study of peripheral IGF-1 effects
- Applications in muscle wasting, bone density, and tissue repair models
Sermorelin
The reference GHRH fragment for physiological GH axis stimulation research
Sermorelin is the 29-amino acid N-terminal fragment of endogenous GHRH, representing the minimal active sequence required for full GHRH receptor binding and GH stimulation. Its close structural identity to native GHRH and well-characterised pharmacokinetics have established it as the reference compound for somatotropic axis stimulation testing.
Key Research Findings
- Shortest active GHRH fragment — preserves endogenous pituitary feedback regulation
- GH secretion response correlates with functional pituitary somatotroph reserve
- Well-established safety data across broad population research models
- Predictable response kinetics — gold standard for GH stimulation testing protocols
- Age-related GH decline: sermorelin response as a functional somatotroph ageing marker
Tesamorelin
Trans-3-hexenoic acid modified GHRH for visceral adiposity research
Tesamorelin is a full-length GHRH(1-44) analogue conjugated with trans-3-hexenoic acid, stabilising it against dipeptidyl peptidase-4 cleavage. Research demonstrates a unique specificity for reducing visceral adipose tissue while preserving lean mass, making it a primary tool for studying regional fat distribution mechanisms.
Key Research Findings
- Selective visceral adipose tissue reduction — distinct from subcutaneous fat effects
- Lipolytic GH signalling in visceral fat depots through hormone-sensitive lipase activation
- Improved trunk fat-to-lean ratio in HIV-associated lipodystrophy research models
- Triglyceride and non-HDL cholesterol reduction observed across study cohorts
- Cognitive function: GH-axis restoration and hippocampal IGF-1 upregulation research
Somatotropic Axis Modelling
GH secretagogue research collectively maps the GHRH→Pituitary→GH→IGF-1 axis, enabling study of upstream regulation versus downstream peripheral effects.
Body Composition Studies
Growth hormone peptides are primary research tools for exploring skeletal muscle accretion, adipose tissue reduction, and the GH/IGF-1 axis role in body composition regulation.
Ageing & Somatopause
Age-related GH decline is a central theme, with these peptides used to explore whether restoring GH patterns attenuates age-associated physiological decline.
Inflammatory Modulation Peptide Summaries
Research overviews for peptides demonstrating immunomodulatory, anti-inflammatory, and tissue-protective effects across multiple physiological systems.
Thymosin Alpha-1
Endogenous thymic peptide with broad immunomodulatory research applications
Thymosin Alpha-1 (Tα1) is a 28-amino acid acetylated peptide naturally derived from thymosin fraction 5. Research across immune function models demonstrates its capacity to modulate both innate and adaptive immunity by enhancing T-lymphocyte maturation, dendritic cell function, and NK cell activity, while tempering excessive pro-inflammatory cytokine cascades.
Key Research Findings
- TLR2/TLR9 signalling activation enhancing innate immune pattern recognition
- T-helper cell differentiation and regulatory T-cell balance modulation
- Dendritic cell maturation and antigen-presenting capacity enhancement
- NK cell cytotoxicity amplification in immunosuppressed research models
- IL-2 and IFN-γ upregulation with concurrent IL-10 anti-inflammatory balance
- Sepsis and immunosenescence research across ageing models
KPV
Alpha-MSH C-terminal tripeptide with potent local anti-inflammatory action
KPV (Lys-Pro-Val) is the bioactive C-terminal tripeptide of alpha-melanocyte stimulating hormone. Research demonstrates that KPV retains the anti-inflammatory potency of the parent molecule while offering improved stability. It directly penetrates intestinal epithelial cells and interacts with intracellular inflammatory machinery, making it a valuable tool in gastrointestinal inflammation research.
Key Research Findings
- MC1R and MC3R agonism suppressing NF-κB nuclear translocation
- PepT1 transporter-mediated intestinal epithelial cell uptake demonstrated in vitro
- Colitis models: reduced mucosal IL-1β, TNF-α, and IL-6 secretion
- Direct intracellular anti-inflammatory action independent of receptor binding
- Improved gut barrier integrity markers in inflammation research models
BPC-157
Stable gastric pentadecapeptide with systemic cytoprotective research profile
BPC-157 is a 15-amino acid synthetic peptide derived from a sequence within human gastric juice. Research across multiple tissue systems demonstrates remarkable cytoprotective, anti-inflammatory, and tissue repair properties spanning musculoskeletal, neurological, and vascular research models.
Key Research Findings
- FAK and paxillin phosphorylation promoting fibroblast migration and tendon repair
- eNOS upregulation and NO-mediated vascular protective effects
- COX-2 and NF-κB modulation reducing inflammatory cytokine cascades
- VEGF receptor upregulation promoting neovascularisation in wound healing models
- Neurotrophic effects: BDNF and dopamine pathway stabilisation in CNS research
- Gut-brain axis: vagal afferent modulation and enteric neuroprotection
TB-500
Actin-regulating thymosin beta-4 fragment for tissue repair research
TB-500 is the active fragment of Thymosin Beta-4, specifically the actin-binding domain sequence LKKTETQ. By regulating G-actin sequestration and cytoskeletal dynamics, TB-500 research encompasses cell migration, wound closure, inflammation resolution, and vascular remodelling in musculoskeletal injury and cardiac repair models.
Key Research Findings
- G-actin sequestration regulates cytoskeletal dynamics and cell morphology
- ILK (integrin-linked kinase) pathway activation promoting cell survival signalling
- Keratinocyte and endothelial cell migration enhancement in wound healing studies
- Anti-inflammatory cytokine modulation via NF-κB pathway suppression
- Cardiac progenitor cell activation in myocardial repair research models
- Tendon, muscle, and ligament regeneration — extensively modelled in vivo
Immune Modulation Studies
These peptides provide complementary tools for studying innate and adaptive immune regulation, from pattern recognition to cytokine balance and lymphocyte differentiation.
Tissue Repair Models
BPC-157 and TB-500 are primary research peptides for musculoskeletal injury models, offering mechanistic insight into tendon, ligament, muscle, and bone repair cascades.
GI Inflammation Research
KPV's intestinal uptake pathway and BPC-157's gastric origin make both valuable tools for studying inflammatory bowel conditions and gut epithelial barrier function.
Mitochondrial Function Peptide Summaries
Research overviews for mitochondrial-derived peptides and NAD+ precursor compounds at the frontier of bioenergetics and metabolic health research.
Mitochondrial-Derived Peptide · Featured Summary
MOTS-c
Mitochondrial Open Reading Frame of the 12S rRNA-c
MOTS-c is a 16-amino acid peptide encoded within the mitochondrial 12S rRNA gene — one of the few known peptides of mitochondrial origin. Research demonstrates that MOTS-c functions as a retrograde mitochondrial signal, translocating to the nucleus under metabolic stress to regulate nuclear gene expression, AMPK activation, and whole-body metabolic homeostasis.
- Mitochondrial genome-encoded retrograde signalling peptide — unique biological origin
- AMPK activation improving glucose uptake and insulin sensitivity in skeletal muscle
- Nuclear translocation under metabolic stress to regulate adaptive gene expression
- AICAR pathway engagement mimicking exercise-like metabolic adaptation
- Circulating levels decline with age — mitochondrial decline research parallel
- Longevity and healthspan research in ageing and caloric restriction models
NAD+ Precursors
NMN, NR, and related compounds restoring mitochondrial bioenergetic capacity
NAD+ and its biosynthetic precursors — including NMN and NR — are central to mitochondrial electron transport, sirtuin deacetylase activation, and DNA damage repair. Research models demonstrate that restoring age-related NAD+ decline produces broad mitochondrial and metabolic rejuvenation effects across multiple tissues.
Key Research Findings
- NAD+ decline with ageing — 50%+ reduction in key tissues in animal models
- Sirtuin (SIRT1–SIRT7) activation driving deacetylation of metabolic regulatory proteins
- PARP-1 DNA repair pathway support — genotoxic stress and senescence research
- Mitochondrial biogenesis via PGC-1α activation and NRF2 pathway engagement
- Cognitive function: hippocampal NAD+ restoration and neuroprotective effects
- Skeletal muscle endurance and metabolic efficiency in exercise research models
MOTS-c: Metabolic Detail
Exercise mimetic and metabolic stress-response signalling research
In preclinical models, exogenous MOTS-c administration replicates signatures of endurance exercise at the metabolic level — activating AMPK, suppressing the folate cycle–AICAR axis, and improving insulin-stimulated glucose disposal in peripheral tissues. Research positions it as a novel exercise mimetic with systemic metabolic effects.
Key Research Findings
- Methionine cycle and folate pathway suppression generating AICAR for AMPK activation
- Muscle GLUT4 translocation promoting insulin-independent glucose uptake
- Physical performance enhancement in diet-induced insulin resistance models
- Heat stress response coordination — mitochondrial stress hormone hypothesis
- Circulating MOTS-c as potential ageing biomarker in centenarian studies
Bioenergetics Research
MOTS-c and NAD+ precursors are complementary tools for studying the full spectrum of mitochondrial energy production, from electron transport chain efficiency to substrate utilisation.
Longevity & Ageing Models
Declining mitochondrial function is a hallmark of biological ageing. These compounds allow researchers to probe the causal versus consequential role of bioenergetic decline in ageing.
Exercise Mimicry Studies
MOTS-c's exercise-mimetic properties make it a valuable research tool for studying metabolic adaptation in populations where conventional exercise intervention is not feasible.
Angiogenesis & Tissue Repair Summaries
Research overviews for peptides modulating vascular biology, matrix remodelling, and blood vessel formation in wound healing and regenerative research models.
GHK-Cu
Endogenous copper-chelating tripeptide with broad tissue regenerative research profile
GHK-Cu is an endogenous human plasma tripeptide with high affinity for copper ions. Research demonstrates its role as a multifunctional tissue remodelling agent — activating matrix metalloproteinases, upregulating VEGF signalling, stimulating antioxidant enzyme systems, and promoting wound healing through improved vascularisation and collagen matrix organisation.
Key Research Findings
- Copper delivery to lysyl oxidase enabling collagen and elastin crosslinking maturation
- MMP activation (MMP-1, MMP-2, MMP-9) for extracellular matrix remodelling
- VEGF and FGF expression upregulation promoting endothelial cell proliferation
- SOD and catalase activation reducing oxidative damage in wound environments
- Skin research: dermal collagen density, elasticity, and age-related decline reversal
- Neurotrophin BDNF and NGF upregulation in neural repair research models
BPC-157: Vascular Focus
Neovascularisation and endothelial protection in injury repair research
Beyond its inflammatory modulation profile, BPC-157 has a substantial angiogenesis research portfolio demonstrating its capacity to stimulate VEGF receptor expression, promote endothelial cell tube formation, and restore blood flow to ischaemic tissues — positioning it as a dual anti-inflammatory and pro-angiogenic research tool.
Key Research Findings
- VEGFR2 upregulation accelerating endothelial sprouting in ischaemia models
- eNOS-mediated nitric oxide production supporting vasodilatory and repair responses
- In vivo wound closure acceleration with enhanced capillary density at wound sites
- Ischaemia-reperfusion injury protection via vascular stabilisation mechanisms
- Tendon-to-bone healing via concurrent vascularisation and collagen maturation
TB-500: Vascular Focus
Actin-mediated endothelial cell motility and vascular repair
TB-500's actin-sequestering action is directly relevant to angiogenesis research, as endothelial cell migration and tube formation depend critically on cytoskeletal actin dynamics. Research demonstrates that TB-500 promotes endothelial sprouting, supports pericyte recruitment to nascent vessels, and contributes to vascular maturation in wound repair and cardiac injury models.
Key Research Findings
- G-actin dynamics enabling lamellipodia formation for endothelial cell migration
- Endothelial tube formation in Matrigel assays — pro-angiogenic activity confirmed
- Pericyte recruitment promotion supporting nascent vessel stabilisation
- Cardiac vasculogenesis: progenitor cell mobilisation and coronary vessel repair
- Limb ischaemia models: collateral vessel development and tissue perfusion restoration
Wound Healing Protocols
GHK-Cu, BPC-157, and TB-500 collectively address complementary stages of wound repair — matrix remodelling, neovascularisation, and cytoskeletal-driven cell migration — enabling multi-target research designs.
Cardiac Repair Models
TB-500 and BPC-157 have both been studied in cardiac ischaemia and repair contexts, providing tools for investigating the contribution of peptide-driven angiogenesis to myocardial recovery.
Matrix Biology Research
GHK-Cu's MMP activation and collagen crosslinking effects make it a valuable tool for studying extracellular matrix composition, remodelling dynamics, and age-related structural decline.
Educational Research Resource
All research summaries presented here are intended solely for educational and scientific reference purposes. The peptides described are intended strictly for laboratory and preclinical research applications only. These summaries are not medical advice and do not constitute endorsement of any therapeutic use. Researchers should consult primary literature and applicable institutional guidelines when designing research protocols.